Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
Oncotargets and Therapy|October 17, 2017
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experienceCarsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decreasePhilipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 15, 2019
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practiceSabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, et al.
Der Urologe. Ausg. A|August 18, 2021
[Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer]Dirk Beyersdorff, Kambiz Rahbar, Markus Essler, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
International Journal of Colorectal Disease|December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CTRobert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Molecular Imaging|November 20, 2010
Semiautomatic algorithm for lymph node analysis corrected for partial volume effects in combined positron emission tomography-computed tomographyRalph A Bundschuh, Markus Essler, Julia Dinges, et al.
Breast Cancer Research and Treatment|February 19, 2018
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapyYuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2007
Biomimetic amplification of nanoparticle homing to tumorsDmitri Simberg, Tasmia Duza, Ji Ho Park, et al.
Nuklearmedizin. Nuclear Medicine|May 12, 2020
[68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor ImagingBarbara Kreppel, Florian C Gärtner, Milka Marinova, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Oncotargets and Therapy|October 17, 2017
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experienceCarsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 19, 2022
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decreasePhilipp E Hartrampf, Ralph A Bundschuh, Franz-Xaver Weinzierl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 15, 2019
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practiceSabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, et al.
Der Urologe. Ausg. A|August 18, 2021
[Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer]Dirk Beyersdorff, Kambiz Rahbar, Markus Essler, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
International Journal of Colorectal Disease|December 4, 2008
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CTRobert Rosenberg, Ken Herrmann, Ralf Gertler, et al.
Molecular Imaging|November 20, 2010
Semiautomatic algorithm for lymph node analysis corrected for partial volume effects in combined positron emission tomography-computed tomographyRalph A Bundschuh, Markus Essler, Julia Dinges, et al.
Breast Cancer Research and Treatment|February 19, 2018
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapyYuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2007
Biomimetic amplification of nanoparticle homing to tumorsDmitri Simberg, Tasmia Duza, Ji Ho Park, et al.
Nuklearmedizin. Nuclear Medicine|May 12, 2020
[68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor ImagingBarbara Kreppel, Florian C Gärtner, Milka Marinova, et al.
Pageof 21